23andMe Holding Co.

Good morning and welcome to 23andMe's fiscal 2022 first quarter financial results conference call. As a reminder, this call is being recorded. At this time, all participants are in a listen-only mode. After the prepared remarks, there will be a question and answer session. I would like to hand the call over to Wade Walk, Vice President of Investor Relations, to lead off the call. Thank you. Please go ahead.

Thank you. Before we begin, I encourage everyone to go to investors.23andme.com to find the press release we issued earlier today reporting our financial results for the quarter. A replay of today's webcast will also be available on our website for a limited time within 24 hours after the event. Please note that certain statements made during this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions of future periods, are forward-looking statements. These statements are based solely on information that is now available to us. encourage you to review the section entitled forward-looking statements in our press release which applies to this call also please refer to our sec filings which can be found on our website and the sec's website for discussion of numerous factors that may impact our future performance we also discussed certain non-gap measures important information on our use of these measures and reconciliation to u.s gap may be found in our earnings release joining us on our call today are ann logiski our chief executive officer and co-founder and steve shook our Chief Financial Officer. Kenneth Hillen, our Chief Therapeutics Officer, will join us for Q&A. And now, I'd like to turn the call over to Anne.

Thank you, Wade. During our first fiscal quarter, we continue to make progress developing our genomic health service for customers and advancing our pipeline in the therapeutics business. In the consumer business, we continue to grow our customer base, which is now over 13 million genotype customers. In this last quarter, we added three new genetic risk reports for our 23andMe Plus subscribers, glaucoma, psoriasis, and rosacea. This brings the number of health reports in our product to over 60. We are able to provide new insights to our customers on a regular basis thanks to the unmatched size of our consented database for genetic research. Developing our genomic health service for our customers remains a high priority for our consumer business. This service is designed to integrate genetic health risk information into care with the goal of preventing or better managing disease. We are happy to announce two important new hires in the area of genomic health. Recently, we hired Nora Aboul Hassan and Amy Sturm to strengthen our leadership in genomic medicine. Dr. Abul Hasan is our new Vice President of Genomic Health. She is a physician scientist whose work aims to uncover the clinical impact of human genetic variation in diverse populations and drive the large-scale equitable implementation of genomic medicine. She previously served as Director of Translational Genetics at the Regeneron Genetic Center and most recently was the founding chief of the Division of Genomic Medicine and Clinical Director of the Institute for Genomic Health at the Icahn School of Medicine at Mount Sinai. Amy Sturm is our Director of Population Health Genomics. Amy was most recently a professor at Geisinger Genomic Medicine Institute and Director of the MyCode Genomic Screening and Counseling Program and Cardiovascular Genomic Counseling Program. Amy, who was a past president of the National Society of Genetic Counselors, has over 20 years of experience in leadership, clinical care, research, program development, and implementation in areas that include population genomic screening, cardiovascular genetics and genomics, and digital health technologies. Dr. Abul, Hassan, and Amy are bringing critical leadership and experience in the delivery of genomic medicine to the broad population. We look forward to you hearing from them in the near future. In our therapeutics efforts, we continue to use our research platform to create a pipeline of more than 50 programs backed by human genetic data with two now in phase one clinical trials. We also just started the fifth year of our exclusive target discovery collaboration with GSK. Our collaboration with GSK has been very productive, and we believe GSK's decision to exercise their option for a fifth year further demonstrates the value of our unique database for discovering novel targets for drug development. We believe the new therapeutics that come out of our discovery engine will eventually play a significant role in helping people benefit from the human genome. And with that, I'll turn the call over to Steve to review our financial results for the quarter.